EY-103 a novel Wnt Pathway Agonist for Treatment of DME and neovascular AMD
We discuss remarkable preliminary results from the the use of intravitreal EYE-103, a novel Wnt pathway agonist in the treatment of DME and neovascular AMD with Dr. Charles Wykoff of Houston Texas.